Skip to main content
Clinical Trials/NCT06509815
NCT06509815
Active, Not Recruiting
N/A

Safety, Feasibility, and Efficacy of a Bio-experiential Intervention, Multi-sensory Intervention Room Application (MIRA), During Neurosciences ICU Stay

Icahn School of Medicine at Mount Sinai1 site in 1 country34 target enrollmentAugust 25, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Post Intensive Care Syndrome
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
34
Locations
1
Primary Endpoint
Acceptability of Intervention Measure (AIM)
Status
Active, Not Recruiting
Last Updated
6 months ago

Overview

Brief Summary

The purpose of this research study is to determine the safety, feasibility, and efficacy of a device, MIRA, on the physical, mental, and cognitive health of Neurosciences Intensive Care Unit (NSICU) patients.

The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere, which produces audio and visual immersive experiences. The current device, Model M1, is a prototype developed for sole investigational purposes of this study and is not commercially available.

Participants, who will be patients and staff of the NSICU, will complete questionnaires regarding safety, feasibility, and efficacy. The research team will enroll 20 patient and 15 staff participants. The trial is expected to last 12 months.

Registry
clinicaltrials.gov
Start Date
August 25, 2024
End Date
January 1, 2026
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Neha Dangayach

Associate Professor

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

  • To be eligible to participate in this study, an individual must meet all of the following criteria:
  • For NSICU Staff:
  • Current employee at NSICU
  • Aged \>/= 18
  • For NSICU Patients:
  • Currently admitted to the Mount Sinai Hospital NSICU for any diagnosis OR a Legally Authorized Representative (LAR) for the patient, and expected to stay for at least 48 hours
  • Provision of signed and dated informed consent form (ICF)
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Aged \>/= 18
  • Any sex or gender identity

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Acceptability of Intervention Measure (AIM)

Time Frame: Within 2 days of the device used in the patient room during stay in ICU

Implementation success will be assessed using the Acceptability of Intervention Measure (AIM). AIM is a 4-item measure used to determine the extent to which stakeholders (e.g., parents, providers, administrators) believe an intervention or implementation strategy is acceptable. Total score ranges from a minimum score 4 (unacceptable) to a maximum score 20 (very acceptable), with higher scores indicating greater acceptability of the intervention.

Feasibility of Intervention Measure (FIM)

Time Frame: Within 2 days of the device used in the patient room during stay in ICU

Implementation success will be assessed using the Feasibility of Intervention Measure (FIM). FIM is a 4-item measure used to determine the extent to which an intervention or implementation strategy is feasible to implement. Total score ranges from a minimum of 4 (not feasible) to a maximum of 20 (very feasible), with higher scores indicating greater perceived feasibility of the intervention strategy being evaluated.

Intervention Appropriateness Measure (IAM)

Time Frame: Within 2 days of the device used in the patient room during stay in ICU

Implementation success will be assessed using the Intervention Appropriateness Measure (IAM). IAM is a 4-item measure used to determine the extent to which stakeholders (e.g. parents, providers, administrators) believe an intervention or implementation strategy is appropriate or suitable for the situation. Total score ranges minimum 4 (unacceptable) to maximum 20 (very acceptable), with higher scores indicating greater appropriateness of the intervention strategy being evaluated.

Secondary Outcomes

  • Type of pain medication administration(daily, average 4 days in ICU)
  • Patient Health Questionnaire 9 (PHQ9) Scale Score(Up to 6 months)
  • Response to noxious stimuli and/or touch(Up to 6 months)
  • Generalized Anxiety Disorder 7 Scale Score(Up to 6 months)
  • Intubated pain measured using Critical Care Pain Observation Tool(daily, average 4 days in ICU)
  • Patient Health Questionnaire 2 (PHQ2) Scale Score(Up to 6 months)
  • Motor Status(Up to 6 months)
  • Insomnia Severity Index to measure sleep quality(Up to 6 months)
  • Non-intubated pain measured using Pain Scale(daily, average 4 days in ICU)
  • Awareness of person, place, and time(Up to 6 months)

Study Sites (1)

Loading locations...

Similar Trials